ZYNLONTA® (loncastuximab tesirine-lpyl) – Incidence of Richter's Transformation

Overview

- LOTIS-1 was a Phase 1, open-label, single-arm, multicenter study that evaluated the safety and tolerability of ZYNLONTA monotherapy in 183 adult patients with relapsed or refractory (R/R) B-cell Non-Hodgkin Lymphoma (B-NHL).[1]
    - Six patients (3.3%) had a diagnosis of Richter's Transformation.[1]
    - Two patients out of the six patients included in the efficacy analysis, achieved a complete response (CR), and 1 patient achieved a partial response (PR) respectively.[4]
    - No safety information specific to these groups of patients was evaluated.[4]
- LOTIS-2 was a pivotal Phase 2, multicenter, open-label single-arm study that evaluated the efficacy and safety of ZYNLONTA used as monotherapy in 145 adult patients with R/R diffuse large B-cell lymphoma (DLBCL) following ≥2 lines of prior systemic therapy.[2]
    - Two patients (1.4%) had a diagnosis of Richter's Transformation.[3]
- ADC Therapeutics did not conduct a safety or efficacy analysis in patients with a diagnosis of Richter's Transformation in LOTIS 2.[4]
- Please refer to the full Prescribing Information for more information on the incidence of adverse events.[5]

Literature Search

- A PubMed biomedical literature search conducted on July 18,2025, yielded no relevant data regarding ZYNLONTA and Richter's Transformation.

Relevant Prescribing Information

Section 6: Adverse Reactions[5]

6.1 Clinical Trials Experience

- In this pooled safety population of 215 patients, the most common (>20%) adverse reactions, including laboratory abnormalities, were thrombocytopenia, increased gamma-glutamyltransferase, neutropenia, anemia, hyperglycemia, transaminase elevation, fatigue, hypoalbuminemia, rash, edema, nausea, and musculoskeletal pain.

References

[1] Hamadani M, Radford J, Carlo-Stella C, et al. Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. *Blood*. 2021;137(19):2634-2645. doi:10.1182/blood.2020007512

[2] Caimi PF, Ai WZ, Alderuccio JP, et al. Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase 2 LOTIS-2 study. Haematologica. 2024;109:1184–1193.

[3] Data on File, LOTIS-2 Clinical Study Report. ADC Therapeutics

[4] Data on File, Richter's Transformation Memo. ADC Therapeutics

[5] ZYNLONTA® (loncastuximab tesirine-lpyl) FDA-approved Prescribing Information. October 2022.

ADC Therapeutics encourages all health care professionals to report any adverse events and product quality complaints to medical information at 855-690-0340. Please consult the ZYNLONTA Prescribing Information.